This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Rockwell Medical Run-Up Trade Follows Financing

Stocks in this article: RMTI KERX

WIXOM, MI ( TheStreet) -- Consider a run-up trade in a biotech stock after it raises money. A recent example: Last January, Trius Therapeutics (TSRX) sold 6.3 million shares at a 9% discount to its market price at the time. Over the next two months -- and ahead of results from a clinical trial of its lead antibiotic -- Trius shares ran up more than 50%.

I'm giving this strategy another go with Rockwell Medical (RMTI), marketer of dialysis related products. On Monday, Rockwell closed a $40 million stock offering, which should provide the company with enough cash to fund operations into 2014. Rockwell spends a lot of money and its balance sheet has been weak, so this latest offering -- priced at a small discount to market price -- should alleviate investors concerns about the company's cash and attract new buyers to the stock.

Rockwell's looming catalyst is data from two phase III studies of an experimental soluble iron solution added to the dialysis fluid of kidney dialysis patients in order to prevent iron deficiency and anemia.

The pivotal studies are evaluating the ability of Rockwell's SFP to maintain target hemoglobin levels in kidney dialysis patients. Results from the first study are expected in July, the second in October.

I expect Rockwell shares to rise significantly if the July study results come back positive. Remember Keryx Pharmaceuticals (KERX) shot up from $3 to $10 based on positive results from a phase III study of its iron-based phosphate binder in kidney dialysis. Rockwell's SFP is a potential Keryx competitor.

Of course, I trade the run-ups into biotech catalysts and rarely, if ever, risk my capital on the actual event. With Rockwell's balance sheet strengthened, I'm betting on investors running the stock up into the July release of SFP clinical trial results. I'll be exiting my position before July.

Messier is long Rockwell Medical.

Mark Messier is the founder of Messier is a DOJ-certified Criminal Intelligence Analyst and former IT professional, specializing in law enforcement applications. In 2008, Messier began trading biotech stocks, using his analytical expertise to detect and capitalize on human and market patterns. Starting with only $2,200 in his trading account, he has booked over $400,000 in profit in just 4 years. In April 2010, Messier founded the subscription-based stock-trading web site to share his biotech trading ideas with the online investor community. Messier enjoys spending time with his wife and two young boys and visiting his "home away from home" in Costa Rica.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,918.16 +113.36 0.64%
S&P 500 2,073.65 +3.00 0.14%
NASDAQ 4,773.1120 +7.7320 0.16%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs